A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
Stefano Sacchi(University of Modena and Reggio Emilia), Luciano Masini(Casa di Cura Villa Garda), Gabriele Buda(Azienda Ospedaliera Universitaria Pisana), Nicola Di Renzo(Presidio Ospedaliero), Fortunato Morabito(Azienda Ospedaliera di Cosenza), Giuseppe Polimeno, A. Pastorini, Pellegrino Musto(University of Bari Aldo Moro), Ugo Consoli(Ospedale Garibaldi), Alberto Fragasso(Presidio Ospedaliero), Antonio Lazzaro(Guglielmo da Saliceto Hospital), Maria Luigia Vigliotti(Ospedale Sant'Anna), Santo Neri(Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte), Alessandra Zoboli(Azienda Sanitaria Unità Locale di Reggio Emilia), Raimondo Ferrara(Ospedale Policlinico San Martino), Enrico Balleari(Ospedale Policlinico San Martino), Giovanni Quarta(Ospedale Papa Giovanni XXIII), Raffaella Marcheselli
Cited by 28
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
|Journal of Clinical Oncology|2007|374